Literature DB >> 1446709

Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7.

F J Kos1, A Müllbacher.   

Abstract

The present study investigated whether a short synthetic peptide NPP, with a modified sequence (147-158 R156-) derived from influenza A virus nucleoprotein with high affinity for Kd major histocompatibility complex class I molecules, could induce primary influenza virus-specific cytotoxic T (Tc) cells in vitro. Naive BALB/c (H-2d) splenocytes did not respond to the stimulation with only NPP with the generation of effector Tc cells specific for influenza A virus-infected target cells in vitro. However, they were able to do so if cultured with NPP in the presence of IL-7. IL-7 activity in this system differed significantly from IL-2 activity in the specificity of the effect. The use of exogenous IL-2, instead of IL-7, with NPP resulted in the induction of lytic cells that lysed both influenza virus-infected and uninfected syngeneic target cells. These results suggest that IL-7 is a potent regulatory cytokine in the antigen-specific activation of resting naive Tc cell precursors and may provide the necessary conditions for the induction of human primary Tc cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446709     DOI: 10.1002/eji.1830221224

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

Authors:  L K Selin; S R Nahill; R M Welsh
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

2.  Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins.

Authors:  S Hou; X Y Mo; L Hyland; P C Doherty
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

3.  Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization.

Authors:  W S Gallichan; K L Rosenthal
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

4.  Interleukin-7 enhances antimicrobial activity against Leishmania major in murine macrophages.

Authors:  A Gessner; M Vieth; A Will; K Schröppel; M Röllinghoff
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

5.  Concurrent production of interleukin-2, interleukin-10, and gamma interferon in the regional lymph nodes of mice with influenza pneumonia.

Authors:  S R Sarawar; P C Doherty
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Requirement of CD4+ T cells and antigen-presenting cells for primary in vitro generation of CD8+ cytotoxic T cells against Ld-binding self-peptide p2Ca.

Authors:  H Wada; T Ono; A Uenaka; M Monden; E Nakayama
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

7.  The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen.

Authors:  A Müllbacher
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

Review 8.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

9.  Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

Authors:  P Möller; Y Sun; T Dorbic; S Alijagic; A Makki; K Jurgovsky; M Schroff; B M Henz; B Wittig; D Schadendorf
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  IL-7 receptor recovery on CD8 T-cells isolated from HIV+ patients is inhibited by the HIV Tat protein.

Authors:  Elliott M Faller; Mark J McVey; Paul A MacPherson
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.